- Trials with a EudraCT protocol (137)
- Paediatric studies in scope of Art45 of the Paediatric Regulation (0)
137 result(s) found for: Suicidality.
Displaying page 1 of 7.
EudraCT Number: 2015-004745-70 | Sponsor Protocol Number: 55438 | Start Date*: 2018-11-06 |
Sponsor Name:Academic Medical Center (AMC) | ||
Full Title: Efficacy of intranasal ketamine on acute suicidality, a double blind randomized placebo-controlled trial (Ketamine Trial Amsterdam, KETA) | ||
Medical condition: Acute suicidality, which is a rapid increase in suicidal ideation or behaviour from the patient's 'baseline' in the last 24 hours. | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: NL (Ongoing) | ||
Trial results: (No results available) |
EudraCT Number: 2020-002905-24 | Sponsor Protocol Number: 74304 | Start Date*: 2021-07-07 |
Sponsor Name:University Medical Center Groningen | ||
Full Title: Efficacy and feasibility of intranasal ketamine on acute suicidality, a double blind randomized placebo-controlled trial (Ketamine Trial for Acute suicidalty, KETA) | ||
Medical condition: Acute suicidality, which is a rapid increase in suicidal ideation or behaviour from the patient's 'baseline' in the last 24 hours. | ||
Disease: | ||
Population Age: Adults | Gender: Male, Female | |
Trial protocol: NL (Ongoing) | ||
Trial results: (No results available) |
EudraCT Number: 2010-021024-10 | Sponsor Protocol Number: 019-2010 | Start Date*: 2011-04-19 |
Sponsor Name:Organisation name was not entered | ||
Full Title: Anit-Inflammatory treatment to decrease suicidality in patients with a recent suicide attempt and a depressive disorder | ||
Medical condition: Patients with a recent suicide attempt and a depressive disorder | ||
Disease: | ||
Population Age: Adults | Gender: Male, Female | |
Trial protocol: SE (Ongoing) | ||
Trial results: (No results available) |
EudraCT Number: 2012-005510-20 | Sponsor Protocol Number: C10953/1100 | Start Date*: 2013-03-07 |
Sponsor Name:Cephalon, Inc. | ||
Full Title: A Randomized, Open-Label Study to Characterize the Pharmacokinetics, Pharmacodynamics, and Safety of Single and Multiple Doses of Armodafinil (50, 100, and 150 mg/day) in Children and Adolescents w... | ||
Medical condition: Excessive Sleepiness associated with Narcolepsy | ||
Disease: | ||
Population Age: Children, Adolescents, Under 18 | Gender: Male, Female | |
Trial protocol: FI (Prematurely Ended) | ||
Trial results: View results |
EudraCT Number: 2014-002451-26 | Sponsor Protocol Number: 538264464328 | Start Date*: 2015-05-15 | |||||||||||
Sponsor Name:Department of Psychiatry, Helsinki University Central Hospital | |||||||||||||
Full Title: The effect of intranasal ketamine on suicidality in severely depressed and suicidal patients. Randomized, placebo-controlled study | |||||||||||||
Medical condition: Depression | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Male, Female | ||||||||||||
Trial protocol: FI (Prematurely Ended) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2016-003992-23 | Sponsor Protocol Number: 54135419SUI3002 | Start Date*: 2017-07-26 | ||||||||||||||||||||||||||
Sponsor Name:Janssen-Cilag International NV | ||||||||||||||||||||||||||||
Full Title: A Double-blind, Randomized, Placebo-controlled Study to Evaluate the Efficacy and Safety of Intranasal Esketamine in Addition to Comprehensive Standard of Care for the Rapid Reduction of the Sympto... | ||||||||||||||||||||||||||||
Medical condition: Major Depressive Disorder with Imminent Risk of Suicide | ||||||||||||||||||||||||||||
|
||||||||||||||||||||||||||||
Population Age: Adults | Gender: Male, Female | |||||||||||||||||||||||||||
Trial protocol: BE (Completed) PL (Completed) CZ (Completed) AT (Completed) LT (Completed) FR (Completed) ES (Completed) | ||||||||||||||||||||||||||||
Trial results: View results |
EudraCT Number: 2013-000970-31 | Sponsor Protocol Number: TUD-ASLith-057 | Start Date*: 2013-11-27 | |||||||||||
Sponsor Name:Technische Universität Dresden | |||||||||||||
Full Title: Randomized, placebo-controlled multicenter trial of lithium plus treatment as usual (TAU) for acute suicidal ideation and behaviour in patients with suicidal major depressive episode | |||||||||||||
Medical condition: Diagnosis of a major depressive episode; inpatient at screening visit; suicidal ideation/behaviour present defined by a clinical rating of ≥ 8 on the Sheehan Suicidality Tracking Scale (S-STS) at... | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Prematurely Ended) | |||||||||||||
Trial results: View results |
EudraCT Number: 2012-004334-42 | Sponsor Protocol Number: 31-08-252 | Start Date*: 2013-02-14 | |||||||||||
Sponsor Name:Otsuka Pharmaceutical Development & Commercialization, Inc. | |||||||||||||
Full Title: A 52-week, Multicenter, Open-label Study to Evaluate the Effectiveness of an Intramuscular Depot Formulation of Aripiprazole (OPC-14597) as Maintenance Treatment in Patients with Bipolar I Disorder | |||||||||||||
Medical condition: Bipolar I disorder | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: HU (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2013-000001-23 | Sponsor Protocol Number: 14861B | Start Date*: 2014-02-27 | |||||||||||
Sponsor Name:H. Lundbeck A/S | |||||||||||||
Full Title: An open-label extension study to evaluate the long-term safety and tolerability of Lu AE58054 as adjunctive treatment to donepezil in patients with mild-moderate Alzheimer's disease | |||||||||||||
Medical condition: Alzheimer´s disease | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: CZ (Completed) DE (Completed) EE (Completed) IT (Completed) BE (Completed) LT (Completed) ES (Completed) DK (Completed) BG (Completed) PT (Completed) GB (Completed) HU (Completed) FI (Completed) HR (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2016-003990-17 | Sponsor Protocol Number: 54135419SUI3001 | Start Date*: 2017-05-18 | ||||||||||||||||||||||||||
Sponsor Name:Janssen-Cilag International NV | ||||||||||||||||||||||||||||
Full Title: A Double-blind, Randomized, Placebo-controlled Study to Evaluate the Efficacy and Safety of Intranasal Esketamine in Addition to Comprehensive Standard of Care for the Rapid Reduction of the Sympto... | ||||||||||||||||||||||||||||
Medical condition: Major Depressive Disorder with Imminent Risk of Suicide | ||||||||||||||||||||||||||||
|
||||||||||||||||||||||||||||
Population Age: Adults | Gender: Male, Female | |||||||||||||||||||||||||||
Trial protocol: SK (Completed) DE (Completed) HU (Completed) ES (Completed) BG (Completed) | ||||||||||||||||||||||||||||
Trial results: View results |
EudraCT Number: 2007-000088-12 | Sponsor Protocol Number: D1443C00012 | Start Date*: 2008-08-18 |
Sponsor Name:Department of Psychiatry, LMU Munich | ||
Full Title: A prospective, single-blinded (rater-blinded), randomized, parallel group study of the efficacy of Quetiapine XR in the treatment of patients with Acute Stress Disorder (DSM-VI 308.3) | ||
Medical condition: 40 patients with Acute Stress Disorder will be recruited within 2 years. The subjects must meet DSM- IV criteria for acute stress disorder (no acute suicidality) and will be treated with Quetiapine... | ||
Disease: | ||
Population Age: Adults | Gender: Male, Female | |
Trial protocol: DE (Completed) | ||
Trial results: View results |
EudraCT Number: 2011-001412-65 | Sponsor Protocol Number: A0081106 | Start Date*: 2012-01-25 | |||||||||||
Sponsor Name:Pfizer Inc. 235 East 42nd Street, New York, NY 10017 | |||||||||||||
Full Title: A 12-MONTH OPEN-LABEL STUDY TO EVALUATE THE SAFETY AND TOLERABILITY OF PREGABALIN AS ADJUNCTIVE THERAPY IN PEDIATRIC SUBJECTS 1 MONTH TO 16 YEARS OF AGE WITH PARTIAL ONSET SEIZURES AND PEDIATRIC AN... | |||||||||||||
Medical condition: Partial onset seizures and Primary Generalised Tonic Clonic Seizures | |||||||||||||
|
|||||||||||||
Population Age: Infants and toddlers, Children, Adolescents, Under 18, Adults | Gender: Male, Female | ||||||||||||
Trial protocol: HU (Completed) CZ (Completed) PL (Completed) EE (Completed) SE (Completed) BE (Completed) FR (Completed) IT (Completed) BG (Completed) GR (Completed) NL (Completed) LT (Completed) FI (Completed) AT (Completed) SK (Completed) ES (Completed) GB (Completed) DE (Completed) HR (Completed) PT (Not Authorised) DK (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2022-000430-42 | Sponsor Protocol Number: 67953964MDD3003_VENTURA-LT | Start Date*: 2023-06-22 | |||||||||||
Sponsor Name:Janssen-Cilag International NV | |||||||||||||
Full Title: An Open-label, Long-term, Safety and Efficacy Study of Aticaprant as Adjunctive Therapy in Adult and Elderly Participants With Major Depressive Disorder (MDD) | |||||||||||||
Medical condition: Major Depressive Disorder (MDD) | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: SE (Trial now transitioned) HU (Trial now transitioned) BE (Trial now transitioned) CZ (Trial now transitioned) PL (Trial now transitioned) BG (Trial now transitioned) FR (Trial now transitioned) ES (Ongoing) PT (Trial now transitioned) SK (Trial now transitioned) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2015-001884-38 | Sponsor Protocol Number: I5Q-MC-CGAJ | Start Date*: 2015-12-07 |
Sponsor Name:Eli Lilly and Company | ||
Full Title: A Phase 3, Long-Term, Open-Label Safety Study of LY2951742 in Patients with Migraine. | ||
Medical condition: Episodic or chronic migraine headache | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: HU (Completed) BE (Completed) FR (Completed) | ||
Trial results: View results |
EudraCT Number: 2017-004611-38 | Sponsor Protocol Number: AV002 | Start Date*: 2018-10-09 | |||||||||||
Sponsor Name:Bond Avillion 2 Development LP | |||||||||||||
Full Title: A phase 2b randomized, double-blind, placebo controlled, multi-center 12-week study with an additional 40-week follow-up assessment of efficacy, safety and tolerability of M1095 in subjects with mo... | |||||||||||||
Medical condition: Moderate to severe chronic plaque-type psoriasis | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: CZ (Completed) BG (Completed) HU (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2010-023263-18 | Sponsor Protocol Number: A0081105 | Start Date*: 2013-06-12 | |||||||||||
Sponsor Name:Pfizer Inc 235 East 42nd Street, New York, NY10017 US | |||||||||||||
Full Title: A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL GROUP, MULTI-CENTER TRIAL OF PREGABALIN AS ADJUNCTIVE THERAPY IN PEDIATRIC AND ADULT SUBJECTS WITH PRIMARY GENERALIZED TONIC-CLONIC SEIZURES | |||||||||||||
Medical condition: Primary Generalised Tonic Clonic Seizures | |||||||||||||
|
|||||||||||||
Population Age: Children, Adolescents, Under 18, Adults | Gender: Male, Female | ||||||||||||
Trial protocol: CZ (Completed) GB (Completed) HU (Completed) LT (Completed) NL (Completed) SK (Completed) AT (Completed) BG (Completed) ES (Completed) PL (Completed) EE (Completed) GR (Completed) BE (Completed) HR (Completed) DK (Completed) PT (Not Authorised) DE (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2013-004444-31 | Sponsor Protocol Number: KWMP001 | Start Date*: 2015-01-09 |
Sponsor Name: | ||
Full Title: Effects and consequences for mother and child from treatment for depression A prospective randomized, placebo- controlled, trial with internet-based cognitive behavior therapy and sertraline or... | ||
Medical condition: Prosepctive randomized two armed study to evaluate moderate depression during pregnancy treated with interbnetbased CBT and sertarline or placebo and longterm outcome in the children.Secondary obj... | ||
Disease: | ||
Population Age: Adults | Gender: Female | |
Trial protocol: SE (Prematurely Ended) | ||
Trial results: (No results available) |
EudraCT Number: 2017-004834-26 | Sponsor Protocol Number: 2017-12 | Start Date*: 2018-09-05 | |||||||||||
Sponsor Name:Albert Schweitzer hospital | |||||||||||||
Full Title: Influence of dose interval on the pharmacokinetics of both unbound and total fractions of clozapine and norclozapine in psychiatric patients in the Netherlands | |||||||||||||
Medical condition: Schizophrenia | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Male, Female | ||||||||||||
Trial protocol: NL (Ongoing) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2005-001217-17 | Sponsor Protocol Number: Max-Planck-Institute of Psychiatry | Start Date*: 2005-09-12 |
Sponsor Name:Max-Planck-Institute of Psychiatry | ||
Full Title: Comparison of venlafaxine augmentation with lamotrigine, quetiapine, or placebo in treatment resistant depression | ||
Medical condition: Treatment resistant depression | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: DE (Ongoing) | ||
Trial results: (No results available) |
EudraCT Number: 2018-003002-12 | Sponsor Protocol Number: CMIJ821X2201 | Start Date*: 2019-04-08 | |||||||||||
Sponsor Name:Novartis Farmacéutica, S.A. | |||||||||||||
Full Title: A multi-center, randomized, subject and investigator-blinded, placebo-controlled, active comparator, parallel-group proof of concept study to evaluate the efficacy, safety, tolerability, and pharma... | |||||||||||||
Medical condition: Treatment Resistant Depression | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Male, Female | ||||||||||||
Trial protocol: ES (Completed) | |||||||||||||
Trial results: View results |
Subscribe to this Search
To subscribe to the RSS feed for this search click here
.
This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
To subscribe to the RSS feed for this search click here

Download Options: | |
---|---|
Number of Trials to download: | |
Download Content: | |
Download Format: | |
Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial. |
